iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Metropolis Healthcare slumps after weak Q2 performance

9 Nov 2022 , 09:59 AM

Reported EBIDTA fell by 11% to Rs 81.1 crore in Q2 FY23 from Rs 90.6 crore in Q2 FY22. Reported EBIDTA margin was 27% in Q2 FY23 as against 30% in Q2 FY22. Profit before tax in Q2 FY23 stood at Rs 54.8 crore in Q2 FY23, down by 29% from Rs 77.7 crore in Q2 FY22. Metropolis said that its profitability was impacted on account of finance cost going up due to higher interest cost on account of acquisition & impact of foreign exchange; and higher depreciation on account of investments done to fuel the future growth engines. Ameera Shah, promoter and managing director, Metropolis Healthcare, said: ?I am extremely pleased to share that we have recorded highest ever quarterly revenue (excl. covid PCR & covid allied tests) with 16% growth on year-on-year basis. With accelerated shift from the unorganised to the organised sector coupled with increased health awareness amongst customers and a trusted scientific image with medical fraternity, we expect the revenues growth to improve and margins to sustain at the pre-covid levels. We have seen growth in our volumes & patient count and with increased investments in digital & marketing, manpower & customer experience initiatives, we are optimistic of sustaining the growth going forward. Our revenue contribution from wellness segment has increased to 12% in Q2FY23 & has witnessed a healthy growth of 40% on YoY basis.? Metropolis Healthcare is a leading diagnostics company in India with a widespread presence in 20 states & 220 cities. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 172 labs, 3,379 collection centres and 10,000 plus touch points. Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.